SCHEMBL3663544

SCHEMBL3663544

NC(=O)N1CCc2nc(-c3ccc(O[C@H]4C[C@H](N5CCCCC5)C4)cc3)sc2C1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.47
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
DPP4 P27487 5/20 0.40
DPP8 Q6V1X1 5/20 0.40
DPP7 Q9UHL4 5/20 0.40
DPP9 Q86TI2 4/20 0.40
TLR8 Q9NR97 2/20 0.38
TLR7 Q9NYK1 2/20 0.38
GRM5 P41594 3/20 0.36
TLR9 Q9NR96 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3663543 1.00 HRH3 (0.47) HRH3NPC1RAB9ADPP4DPP8
SCHEMBL3669450 0.93 HRH3 (0.45) HRH3NPC1RAB9ADPP4DPP8
SCHEMBL3669447 0.93 HRH3 (0.45) HRH3NPC1RAB9ADPP4DPP8
SCHEMBL3667075 0.93 HRH3 (0.47) HRH3NPC1RAB9ADPP4DPP8
SCHEMBL3667072 0.93 HRH3 (0.47) HRH3NPC1RAB9ADPP4DPP8
SCHEMBL3664942 0.91 HRH3 (0.49) HRH3NPC1RAB9ADPP4DPP8
SCHEMBL3665906 0.91 HRH3 (0.49) HRH3NPC1RAB9ADPP4DPP8
SCHEMBL3664945 0.91 HRH3 (0.49) HRH3NPC1RAB9ADPP4DPP8
SCHEMBL3665904 0.91 HRH3 (0.49) HRH3NPC1RAB9ADPP4DPP8
SCHEMBL3665039 0.90 NPC1 (0.47) HRH3NPC1RAB9ADPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292188-A1 Compounds Comprising A Cyclobutoxy Group UCB PHARMA S.A. (BE) 2010-11-18 US claimed
EP-2238144-A1 COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP UCB Pharma, S.A. (BE) 2010-10-13 EP claimed
WO-2009092764-A1 COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP UCB PHARMA, S.A. (BE) 2009-07-30 WO claimed
US-20100292188-A1 Compounds Comprising A Cyclobutoxy Group UCB PHARMA S.A. (BE) 2010-11-18 US disclosed
US-20100292188-A1 Compounds Comprising A Cyclobutoxy Group UCB PHARMA S.A. (BE) 2010-11-18 US disclosed
US-20100292188-A1 Compounds Comprising A Cyclobutoxy Group UCB PHARMA S.A. (BE) 2010-11-18 US disclosed
EP-2238144-A1 COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP UCB Pharma, S.A. (BE) 2010-10-13 EP disclosed
WO-2009092764-A1 COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP UCB PHARMA, S.A. (BE) 2009-07-30 WO disclosed
WO-2009092764-A1 COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP UCB PHARMA, S.A. (BE) 2009-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292188-A1 Compounds Comprising A Cyclobutoxy Group CYP11B2, CYP11B1, CYP4B1 HRH3 2630/4885NPC1 162/4885RAB9A 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.